Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model

Radiation Research

Volumn 152, Issue 5, 1999, Pages 499-507

  Hamstra, Daniel A ^a   Rice, David J ^a   Anthony, Pu ^a   Oyedijo, Dotun ^a   Ross, Brian D ^a   Rehemtulla, Alnawaz ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER SURVIVAL; CONTROLLED STUDY; HEAD CANCER; IN VIVO STUDY; MOUSE; MULTIMODALITY CANCER THERAPY; NECK CANCER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROVIRUS; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; COMBINED MODALITY THERAPY; CYTOSINE DEAMINASE; DISEASE MODELS, ANIMAL; FLUCYTOSINE; HEAD AND NECK NEOPLASMS; MICE; NUCLEOSIDE DEAMINASES; PRODRUGS; RETROVIRIDAE; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0032740736     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.2307/3580146     Document Type: Article

References (21)

1. E. E. Vokes, Head and neck cancer. In The Chemotherapy Source Book (M. C. Perry, Ed.), 2nd ed., pp. 1083-1101. Williams and Wilkins, Baltimore, 1998.
2. E. E. Vokes, R. R. Weichselbaum, S. M. Lipman and W. K. Hong, Head and neck cancer. N. Engl. J. Med. 328, 184-194 (1993).
3. N. L. Bartlett and T. H. Wasserman, Combined modality therapy. In The Chemotherapy Source Book (M. C. Perry, Ed.), 2nd ed., pp. 109-126. Williams and Wilkins, Baltimore, 1998.
4. E. E. Vokes and R. R. Weichselbaum, Concomitant chemoradiotherapy: Rationale and clinical experience in patients with solid tumors. J. Clin. Oncol. 8, 911-934 (1990).
5. I. Niculescu-Duvaz, R. Spooner, R. Marais and C. J. Springer, Gene-directed enzyme prodrug therapy. Bioconjug. Chem. 9, 4-22 (1998).
6. R. Stupp and E. E. Vokes, 5-Fluorouracil plus radiation for head and neck cancer. J. Infus. Chemother. 5, 55-59 (1995).
7. J. E. Bennett, Antimicrobial agents: Antifungal agents. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. (J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon and A. G. Gilman, Eds.), pp. 1175-1190. McGraw-Hill, New York, 1996.
8. B. E. Huber, C. A. Richards and T. A. Krenitsky, Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA 88, 8039-8043 (1991).
9. M. Khil, J. Kim, C. Mullen, S. Kim and S. Freytag, Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine-deaminase gene. Clin. Cancer Res. 2, 53-57 (1996).
10. N. N. Hanna, H. J. Mauceri, J. D. Wayne, D. E. Hallahan, D. W. Kufe and R. R. Weichselbaum, Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res. 57, 4205-4209 (1997).
11. L. C. Pederson, D. J. Buchsbaum, S. M. Vickers, S. R. Kancharla, M. S. Mayo, D. T. Curiel and M. A. Stackhouse, Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res. 57, 4325-4332 (1997).
12. B. W. O'Malley, Jr., D. A. Sewell, D. Li, K. Kosai, S. H. Chen, S. L. Woo and L. Duan, The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer. Mol. Endocrinol. 11, 667-673 (1997).
13. T. S. Lawrence, A. Rehemtulla, E. Y. Ng, M. Wilson, J. E. Trosko and P. L. Stetson, Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res. 58, 2588-2593 (1998).
14. T. S. Lawrence, Reduction of doxorubicin cytotoxicity by ouabain: correlation with topoisomerase-induced DNA strand breakage in human and hamster cells. Cancer Res. 48, 725-730 (1988).
15. D. A. Hamstra and A. Rehemtulla, Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/Furin family of propeptidases. Hum. Gene Ther. 10, 235-248 (1999).
16. E. Kievit, E. Bershad, E. Ng, P. Sethna, I. Dev, T. S. Lawrence and A. Rehemtulla, Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. 59, 1417-1421 (1999).
17. B. W. O'Malley, Jr., K. A. Cope, C. S. Johnson and M. R. Schwartz, A new immunocompetent murine model for oral cancer. Arch. Otolaryngol. Head Neck Surg. 123, 20-24 (1997).
18. A. Dinesman, B. Haughey, G. A. Gates, T. Aufdemorte and D. D. Von Hoff, Development of a new in vivo model for head and neck cancer. Otolaryngol. Head Neck Surg. 103, 766-774 (1990).
19. M. Fields, A. Eisbruch, M. A. Davis, A. Pu and T. S. Lawrence, Radiosensitization produced by once vs twice weekly gemcitabine. Int. J. Radiat. Oncol. Biol. Phys. 42 (Suppl. 1), 202 (1998). [Abstract]
20. B. D. Ross, Y. J. Zhao, E. R. Neal, L. D. Stegman, M. Ercolani, O. Ben-Yoseph and T. L. Chenevert, Contributions of cell kill and post-treatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: an MRI study. Proc. Natl. Acad. Sci. USA 95, 7012-7017 (1998).
21. D. A. Hamstra, D. J. Rice, S. Fahmy, B. D. Ross and A. Rehemtulla, Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum. Gene Ther., in press.